Oncology · Non-small Cell Lung CancerTrial Updateclinicalmid-term

Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 12:32:54 AM

Assessment confidence: 69% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of this trial represents a significant advancement in the treatment landscape for non-small cell lung cancer (NSCLC). If successful, it could provide a new therapeutic option, thereby altering treatment protocols and competitive dynamics in oncology. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (13 high-relevance).

Strategic Assessment

Success in this trial may lead to a new treatment option in the adjuvant setting for NSCLC, impacting market dynamics and treatment protocols. The strongest clinical anchor is A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (merck). In lung cancer, 5 regulatory and 5 competitive items passed relevance filtering for Merck.

Competitive Pressure

The most relevant competitive pressure comes from Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (merck). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (Merck); Regulatory pathway relevance (approval). The trial's results will be critical for future regulatory submissions, influencing approval timelines and labeling for the new treatment option.

Key Risks

Elevated medium regulatory exposure for Merck could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Merck through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

A successful outcome could lead to a new product launch, enhancing market share for Merck and Moderna while potentially displacing existing therapies in the NSCLC segment.
To compare the efficacy and safety of a sequential combination of chemoradiotherapy (CRT) with immune checkpoint inhibitors (ICIs) administered as induction plus consolidation versus consolidation-only in patients with unresectable stage III non-small cell lung cancer (NSCLC).
Upside for Merck may improve if An automatic detection model for spread through air spaces in postoperative pathological sections based on deep learning in NSCLC. (PubMed) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for disease-free survival outcomes and any updates on patient recruitment and interim analyses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (nda)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (merck)
FDA document
View source
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (AstraZeneca)
FDA document
View source
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source

Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment
Humanexa Signalsmedium relevance
Entity match (merck)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Entity match (merck)
FDA document
View source
Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalsmedium relevance
Entity match (merck)

Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
An automatic detection model for spread through air spaces in postoperative pathological sections based on deep learning in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Merck
Moderna
existing NSCLC therapies

Commercial impact

high

A successful outcome could lead to a new product launch, enhancing market share for Merck and Moderna while potentially displacing existing therapies in the NSCLC segment.

Regulatory impact

medium

The trial's results will be critical for future regulatory submissions, influencing approval timelines and labeling for the new treatment option.

What to watch

Monitor trial results for disease-free survival outcomes and any updates on patient recruitment and interim analyses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.